anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Devices, systems, and methods for orthodontic treatment planning and orthodontic treatment are disclosed herein. Various embodiments are directed to a method of obtaining data characterizing movements of a patient's teeth from original positions to desired, final positions. The method can include identifying one or more components of the movements, evaluating the movements, and/or modifying the movements. The method can comprise obtaining an orthodontic treatment plan, which can include one or more suggested interventions to accomplish the tooth movements, a design of such intervention(s), and/or other useful information regarding the orthodontic treatment. The method may comprise evaluating an orthodontic treatment during and/or after implementation of the treatment, which can include obtaining data characterizing current positions of the patient's teeth. Based on the evaluation, the method can include obtaining another orthodontic treatment plan and movement data characterizing movements of a patient's teeth from their current positions to desired, final positions.
As a common musculoskeletal disorder, frozen shoulder is characterized by thickened joint capsule and limited range of motion, affecting 2-5% of the general population and more than 20% of patients with diabetes mellitus. Pathologically, joint capsule fibrosis resulting from fibroblast activation is the key event. The activated fibroblasts are proliferative and contractive, producing excessive collagen. Albeit high prevalence, effective anti-fibrosis modalities, especially fibroblast-targeting therapies, are still lacking. In this study, microRNA-122 was first identified from sequencing data as a potential therapeutic agent to antagonize fibroblast activation. Then, Agomir-122, an analog of microRNA-122, was loaded into poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Agomir-122@NP), a carrier with excellent biocompatibility for the agent delivery. Moreover, relying on the homologous targeting effect, we coated Agomir-122@NP with the cell membrane derived from activated fibroblasts (Agomir-122@MNP), with an attempt to inhibit the proliferation, contraction, and collagen production of abnormally activated fibroblasts. After confirming the targeting effect of Agomir-122@MNP on activated fibroblasts in vitro, we proved that Agomir-122@MNP effectively curtailed fibroblasts activation, ameliorated joint capsule fibrosis, and restored range of motion in mouse models both prophylactically and therapeutically. Overall, an effective targeted delivery method was developed with promising translational value against frozen shoulder.
IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
All patients included in the study underwent a spontaneous breathing trial (SBT) using pressure support ventilation (PSV) strategy. This strategy employed pressure support(PS)≤9 cmH2O and positive end-expiratory pressure (PEEP)≤5 cmH2O. The duration of the trial was 30 minutes, and the FiO2 level was set at the same level (≤0.5) used during mechanical ventilation. After successful completion of the spontaneous breathing trial (SBT), ultrasound images were promptly acquired, and the Rapid Shallow Breathing Index (RSBI) was calculated based on the values displayed by the ventilator . Simultaneously, the Acute Physiology and Chronic Health Evaluation II (APACHE II) score was computed and recorded. The decision to extubate, made by the attending physician (unaware of the ultrasound examination parameters), was based on clinical judgment. The primary endpoint event was extubation failure, defined as successful completion of SBT but an inability to sustain spontaneous breathing for more than 48 hours without noninvasive or invasive ventilation support.
The invention discloses a traditional Chinese medicine preparation for treating pelvic inflammation and a preparation method thereof, and belongs to the field of traditional Chinese medicine. The traditional Chinese medicine preparation is effectively prepared from dysosma, herb of Clubhead Cutgrass, Woodfordiafruticosa(Linn.)Kurz, Millettia reticuiata Benth., burmann cinnamon bark, Melastoma dodecandrum Lour., Curcuma longa L, roots of Coix lacryma-jobi L., roots of Spine Aralia, stellaria media, roots of Averrhoa carambola, Carica Papaya L., placentae, opuntia stricta, Balanophora harlandii Hook. F.[Balania harlandii (Hook.f.)van Tiegh.) and roots of kumquat. Compatibility of medicinal materials selected for the traditional Chinese medicine preparation is appropriate and conforms to the theories of traditional Chinese medicine and pharmacology and modern medicine and pharmacology. The traditional Chinese medicine preparation has the functions of activating blood circulation and eliminating toxicant, clearing heat and dispersing blood stasis, and reducing swelling to relieve pain, has a remarkable treatment effect on treating pelvic inflammation, is short in treatment course and quick in effect, makes patients not prone to relapse after cure, and is safe, reliable, free of any toxic and side effect, capable of achieving the aim of treating both symptoms and root causes, strong in effect, practical and worthy of wide clinical application and popularization.
Aim of the Study: The aim of this research is to compare the effectiveness of tell show and do (TSD) vs puppet play therapy on children's behavior during the administration of local anesthesia.

Materials and Methods: This was a randomized crossover clinical trail that was conducted at King Abdulaziz University Faculty of Dentistry for a period of 12 months starting from Jan 2023 to Dec 2023 on 41 children (aged 3-7 years) randomly divided into two groups of. Group I (23 children): Children who received the TSD behavior guidance during their first visit and puppet play therapy in their second visit 2 weeks later. Group II (18 children): Children who received puppet play therapy during their first visit and TSD guidance in their second visit 2 weeks later. The anxiety level was determined using Facial Index Scale(FIS) and Venham anxiety rating scale and pulse rate (PR) at the beginning, middle and the end of each anesthesia administration. Patient behavior was also scored using Frankl behavior rating scale (FBRS) , Venham behavior rating scale. The FLACC scale was used to assess pain.
FIELD: chemistry. ^ SUBSTANCE: invention relates to novel flavonoid compounds of formula 1 where R1-R5 assume values given in the description. The invention also relates to a pharmaceutical composition based on said compounds and a treatment and prevention method. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts are used in pharmaceutical, veterinary and nutraceutical fields. ^ EFFECT: compounds and compositions have antioxidant properties and are especially effective in treating ischemic and reperfusion injury. ^ 39 cl, 19 dwg
PURPOSE: A complex powder and a cosmetic composition containing the same are provided to excellently cover skin spots and enable natural skin expression. CONSTITUTION: A complex powder contains powder and particulate powder. The powder has curved surface and/or flat surface. The surface is coated with the particulate powder. The powder has a hemi spherical, semi-elliptical, disk, cylindrical, tetrahedral, or pyramide shape. The powder is formed of silica, alumina, nylon, methyl methacrylate, polymethyl methacrylate, silicone elastomer, acryl-based polymer, methyl siloxane net-shaped polymer, crosslinking dimethyl polysiloxane, or a plant-derived extract. A cosmetic composition contains 2-80 wt% of the composite powder as an active ingredient.
The utility model relates to a vitamin U belladonna aluminum II micro pill which belongs to the technical field of medicine, particularly a novel dosage type of vitamin U belladonna aluminum II. The utility model makes the vitamin U belladonna aluminum II into a micro pill of 0.8 to 1 millimeter. A layer of instant film coat is coated on the surface of a contenting article in the micro pill. Then, the micro pill is arranged in a capsule. The instant film coat is hydroxypropyl methyl cellulose or ethyl cellulose. The instant film coat can be added with edible pigments of different colors to make the appearance of the micro pill achieve a beautiful effect. The utility model makes a single dose changed into a plurality of doses. After a hard capsule is disintegrated, because the surface area of the micro pill is added, the micro pill can dissolve and scatter within a short time. The speed of suppressing gastric acid is enhanced. The vitamin U belladonna aluminum II micro pill can rapidly adhere to the surface of a gastric mucosa to have a protective function for achieving the function of enhancing a curative effect. In addition, because the layer of instant film coat is coated on the surface of the vitamin U belladonna aluminum II micro pill, vitamin U contained in the contenting article is difficult to achieve oxidation.
In this randomized, phase IIB, double blind, placebo controlled, multicenter, pre-surgical, window-of-opportunity trial we compared the effects of finasteride (5 mg/day) versus low-dose flutamide (250 mg/day) or placebo on tissue biomarkers in patients with prostate cancer who were candidate to radical surgery. Specifically, the effects of both drugs on the change in epithelial cell nuclear area in prostate cancer tissue between pre- and post-treatment biopsies was evaluated (primary endpoint). Moreover, the changes of the proliferation marker Ki-67 and of karyometric parameters in benign, dysplastic (HG-PIN) and malignant tissues were evaluated (secondary endpoints). Additional endpoints include the changes of serum PSA and testosterone, assessment of toxicity, overall survival, recurrence-free survival and event-free (recurrence + death) survival. Patients with intracapsular biopsy proven prostate cancer were randomized to either flutamide, 250 mg/day, or finasteride, 5 mg/day, or placebo for 4-6 weeks before radical prostatectomy. Blood samples were taken before and after treatment. At surgery, end-of-study ex-vivo biopsies were obtained from the prostatectomy specimens to assess the treatment changes in nuclear area (primary endpoint), Ki-67, topoisomerase-II-α and a 20-feature karyometric discrimant function in normal, high-grade PIN and malignant tissue. After surgery patients were followed up for at least 15 years to assess recurrence and/or mortality. We also plan to follow-up patients by telephone interview to assess their vital status for up to 20 years.
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: The established safety and efficacy of tranexamic acid (TXA) in minimizing perioperative blood loss has led to increased interest within plastic surgery. Prior studies have demonstrated decreased edema and ecchymosis and reduced rates of postoperative collection with administration of TXA; however, its use has not been reported in gender-affirming mastectomy. This represents the first study to evaluate the effects of TXA on postoperative outcomes in patients undergoing gender-affirming mastectomy.
METHODS: A single-center cohort study was performed analyzing all consecutive patients undergoing gender-affirming mastectomy with the senior author (R.B.-L.) between February of 2017 and October of 2022. Beginning in June of 2021, all patients received 1000 mg of TXA intravenously before incision and 1000 mg at the conclusion of the procedure. Patients were stratified according to intraoperative administration of TXA, with demographic characteristics, surgical characteristics, and postoperative outcomes compared between groups.
RESULTS: A total of 851 patients underwent gender-affirming mastectomy. Of these, 646 cases were performed without TXA, and 205 patients received intravenous TXA intraoperatively, as described previously. Patients who received TXA had significantly lower rates of seroma (20.5% versus 33.0%; P < 0.001) and hematoma (0.5% versus 5.7%; P = 0.002). There was no difference in rates of surgical-site infection ( P = 0.74). TXA use was not associated with increased rates of venous thromboembolism ( P = 0.42).
CONCLUSIONS: Intraoperative administration of TXA in patients undergoing gender-affirming mastectomy may safely reduce the risk of postoperative seroma and hematoma without increased risk of thromboembolic events. Additional data collection and prospective studies are warranted to corroborate these findings.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dentistry, and can be used to prepare the bone alveoli for implantation. For this purpose, osteoplastic material is placed in the area of the defect, the augmentation zone is closed, the wound is sutured and the implant is inserted. Bone-substituting material is placed in the defect area directly after tooth extraction into the formed well by filling it with ClipDent-PL osteoplastic material in the form of β-tricalcium phosphate mineral polymer granules, produced in Russia by VladMiVa. Augmentation zone is closed by an autogenous material, the preparation of which is carried out by isolating a horizontal fragment of an extracted tooth with a thickness of at least 2 mm with partial seizure of the root canal. For this purpose, in multi-rooted teeth, a zone below the level of the bifurcation of the roots by 2 mm is used; in single-root teeth, the cervical area is used. Then, the cut surfaces of a fragment of an extracted tooth are coated on both sides with any light-cured material. If the tooth is not previously treated endodontically, mechanical and medical treatment of the root canals is carried out, followed by filling with any light-curing material. Next, a fragment of the extracted tooth is treated in a 2 % chlorhexidine solution. Prepared fragment of the extracted tooth is placed in the hole of the extracted tooth filled with osteoplastic material to a depth of no more than 2 mm and sutured. Implantation in the area of the missing tooth is carried out in 6–10 weeks.EFFECT: method provides a reduction in the time required to obtain the required volume of the alveolar bone to 6–10 weeks while reducing the number of surgical implantation stages.1 cl, 4 dwg, 1 ex
Botulinum toxin type A, the active ingredient in DYSPORT, is a purified neurotoxin type A complex produced by fermentation of the bacterium Clostridium botulinum type A, Hall Strain. It is purified from the culture supernatant by a series of precipitation, dialysis, and chromatography steps. The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins and non-toxin non-hemagglutinin protein.

DYSPORT® (abobotulinumtoxinA) for injection is a sterile, lyophilized powder supplied in a single-dose vial for reconstitution intended for intramuscular injection. Each vial contains 300 Units or 500 Units of lyophilized abobotulinumtoxinA, human serum albumin (125 mcg) and lactose (2.5 mg). DYSPORT may contain trace amounts of cow's milk proteins [see Contraindications (4) and Warnings and Precautions (5.3)].

The primary release procedure for DYSPORT uses a cell-based potency assay to determine the potency relative to a reference standard. The assay and reference material are specific to DYSPORT. One unit of DYSPORT corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. Due to specific details of the assay system, such as vehicle, dilution scheme and laboratory protocols, Units of biological activity of DYSPORT cannot be converted into Units of any other botulinum toxin or any toxin assessed with any other specific assay method.
Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by"3+3" escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles.
ONCOFETAL FIBRONECTIN AS A MARKER FOR DISEASE AND OTHER CONDITIONS AND METHODS FOR DETECTION OF ONCOFETAL FIBRONECTIN 5 Abstract Methods and products for the detection of oncofetal fibronoctin indicating molocules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/r contacted with a 10 non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunossays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronectin for selection of concepti are provided.
The present invention provides compositions and methods for immunotherapy in human. The invention includes a B cell receptor like complex expressed in T cells and comprising an extracellular antigen recognition domain, a trans-membrane domain, a CD79αβ heterodimer, and a signaling region that controls T cell activation. The extracellular antigen recognition domain and trans-membrane are derived from the same human or humanized B cell receptor and form a single unit in the complex. The signaling region comprises a T cell signaling domain in combination with a co-stimulatory signaling domain. The signaling region is fused to the CD79αβ heterodimer. Furthermore, the B cell receptor like complex of the present invention can use a targeting molecule as a bridge between cytotoxic T cells and targeted cells.
The traditional phoropter was administered first in this group, followed by the traditional phoropter. The traditional phoropter is intended to be used for distance vision testing in any environment. The LFR-260 is a portable digital refractor which allows for determination of refractive error as well as for fully remote refractions during eye exams.
PURPOSE:To control the astringent force for a skin astringent extracted from a seaweed belonging to the class Phaeophyceae. CONSTITUTION:An extract from a seaweed belonging to the class Phaeophyceae is fractionated to provide the respective fractions, which are optionally combined to afford this skin astringent having controlled astringent force. The seaweed belonging to the class Phaeophyceae is preferably a seaweed belonging to the order Fucales. As a method for fractionation, a synthetic adsorbent HP-20(R) is used and an eluting solvent is optionally selected to control the astringent force. Thereby, this skin astringent having the optional astringent force utilizable as various cosmetics can be produced from the seaweed extract belonging to the class Phaeophyceae. In addition, beautifying and whitening effects can be controlled.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to otolaryngology, and can be used for treatment of chronic tonsillitis. For this purpose introduced is derinate with simultaneous sanitisation of tonsils with 0.5% dioxydin solution. Derinate is introduced in dose of 5 drops into each nasal passage 3 times per day. Course of treatment is 7 days. Such treatment is carried out not less than one time per six months. ^ EFFECT: invention makes it possible to obtain long-term disease remission and reduce the number of chronic tonsillitis recurrence. ^ 1 ex
It has been discovered that SKF-96365 prevents and reverses ectopic activity in myocyte cells, and that SKF-96365 is effective against all types of ectopic activity.  Methods are provided using SKF-96365 and its derivatives to prevent and reverse electromechanical disorders of myocytes; these include methods of treatment and prevention of cardiac arrhythmias in human and animal subjects.  These further include methods of preventing and reversing arrhythmias in cardiac muscles and hearts. These further include methods of preventing and reversing spontaneous mechanical activity in a myocyte. Pharmaceutical drugs for the treatment and prevention of cardiac arrhythmia are described, based on SKF-96365.  Kits for employing the methods are also described.
This study uses two parallel groups of approximately 100 patients in each arm. After a screening period to confirm eligibility, patients will be randomized to either the RPM system group, or the usual care group. Both groups will be followed for 52 weeks until the end of study. There are only 4 planned study visits and patients will continue on their usual treatment.

The remote patient monitoring system will issue an alert to the clinical site once the established threshold change has been reached. The alert notification will require the clinical site to contact the patient and treat the patient based on clinical judgment and clinical practice. Patients in the usual care arm will be managed through their normally nurse/physician contact.
Standardized rehabilitation involves several strategies tailored to the patient and remains somewhat based on clinician preference. These therapies may involve functional electrical stimulation, neuro-facilitation, strengthening, range of motion (ROM), mirror therapy, and force-use therapy (e.g., CIMT). Patients engage in therapy 5 days per week as inpatients, and 2 days per week as outpatients with additional home exercises. Specific therapies for each patient will be tracked using a therapy log.
This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
Patients with end-stage renal disease (ESRD) suffer from high morbidity and mortality of cardiovascular and infectious disease and increased risk of all-cause mortality which is mainly attributed to the disturbed immune response. More and more evident indicated that T cell dysfunction was universal in ESRD. Recent evidence suggests uremia-related immune changes resemble to aging immune system, increasing immunological age of T cells by 20-30 years. As compared to an age-matched healthy control, ESRD patients present a lower thymic output of naïve T cells, a decline in the T-cell telomere length and an increase in the differentiation status towards the terminal differentiated memory phenotype with a large number of CD28-negative T cells. More importantly, these changes are strongly associated with a history of cardiovascular diseases and the occurrence of severe infectious episodes in this population, supporting the idea that T cell dysfunction is a critical feature in this population and will impact clinical outcomes profoundly. This study prospectively researched the predictive value of T cell dysfunction for all-cause mortality and clinical complication in hemodialysis (HD) patients.